Literature DB >> 16827701

Feasibility and acceptability of the use of artemether-lumefantrine in the home management of uncomplicated malaria in children 6-59 months old in Ghana.

Amanua M Chinbuah1, John O Gyapong, Franco Pagnoni, Edith K Wellington, Margaret Gyapong.   

Abstract

OBJECTIVE: We assessed the feasibility and acceptability of and the willingness to use artemether-lumefantrine (Coartem) during early, appropriate treatment of malaria/fever in children aged 6-59 months at the community and household level in a rural malaria-endemic area in Ghana.
METHOD: In this descriptive study with a pre- post-evaluation of an intervention, community perceptions of fever, health-seeking behaviour and current treatment practices for children aged 6-59 months were ascertained through qualitative research and surveys. The children were counted in a household census and given identification cards. Community-based agents (who were supervised monthly) dispensed a 6-dose-treatment formulation of Coartem over a 4 months period and counseled caregivers on case management and referral. Caregivers who consulted were followed up after 4 days to determine adherence to the treatment regimen. Blister packs of the drugs were inspected where available. The performance of the agents in terms of counselling, advising on referral and reporting was evaluated. Community satisfaction was also assessed qualitatively through focus group discussions and interviews.
RESULTS: Three hundred and sixty-three children sought care during the intervention period. All 235 children aged 6-35 months were correctly provided the one tablet per dose per treatment package compared with 119 of 125 children 36-59 months (95.2%). Only 5 of 17 children were referred appropriately. All 334 caregivers followed the correct drug administration schedule, i.e. twice a day for 3 days. Validation of drugs received indicates that all 204 children aged 6-35 months and 103/118 (87.3%) children aged 36-59 months received the correct drug dose. Adherence of agents and caregivers to the treatment was 308/334 (92.5%). Delay in seeking care was reduced from 3 to 2 days. No serious adverse drug reactions were reported. Community members were enthusiastic about the performance of the agents.
CONCLUSION: A Home Management of Malaria (HMM) strategy with Coartem using trained community-based agents supervised monthly is feasible, acceptable, and can achieve high levels of compliance within Dangme, West District of Ghana. However, if the intervention is to be sustainable, the agents need to be paid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827701     DOI: 10.1111/j.1365-3156.2006.01654.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  52 in total

1.  Community perceptions of malaria and malaria treatment behaviour in a rural district of Ghana: implications for artemisinin combination therapy.

Authors:  Kwaku P Asante; Livesy Abokyi; Charles Zandoh; Ruth Owusu; Elizabeth Awini; Abubakari Sulemana; Seeba Amenga-Etego; Robert Adda; Owusu Boahen; Sylvester Segbaya; Emmanuel Mahama; Constance Bart-Plange; Daniel Chandramohan; Seth Owusu-Agyei
Journal:  BMC Public Health       Date:  2010-07-12       Impact factor: 3.295

2.  In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.

Authors:  Leah Mwai; Steven M Kiara; Abdi Abdirahman; Lewa Pole; Anja Rippert; Abdi Diriye; Pete Bull; Kevin Marsh; Steffen Borrmann; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

3.  Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.

Authors:  Abdunoor M Kabanywanyi; Christian Lengeler; Prudensiana Kasim; Said King'eng'ena; Raymond Schlienger; Nathan Mulure; Blaise Genton
Journal:  Malar J       Date:  2010-02-11       Impact factor: 2.979

4.  Adherence to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana: A Randomised Trial of Supervised versus Unsupervised Drug Administration.

Authors:  Kwaku Poku Asante; Ruth Owusu; David Dosoo; Elizabeth Awini; George Adjei; Seeba Amenga Etego; Daniel Chandramohan; Seth Owusu-Agyei
Journal:  J Trop Med       Date:  2009-10-21

5.  Community acceptability of use of rapid diagnostic tests for malaria by community health workers in Uganda.

Authors:  David Mukanga; James K Tibenderana; Juliet Kiguli; George W Pariyo; Peter Waiswa; Francis Bajunirwe; Brian Mutamba; Helen Counihan; Godfrey Ojiambo; Karin Kallander
Journal:  Malar J       Date:  2010-07-13       Impact factor: 2.979

6.  Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children.

Authors:  Lesong Conteh; Edith Patouillard; Margaret Kweku; Rosa Legood; Brian Greenwood; Daniel Chandramohan
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

7.  Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study.

Authors:  Billy E Ngasala; Maja Malmberg; Anja M Carlsson; Pedro E Ferreira; Max G Petzold; Daniel Blessborn; Yngve Bergqvist; José P Gil; Zul Premji; Andreas Mårtensson
Journal:  Malar J       Date:  2011-03-16       Impact factor: 2.979

Review 8.  The community case management of pneumonia in Africa: a review of the evidence.

Authors:  Thomas Druetz; Kendra Siekmans; Sylvie Goossens; Valéry Ridde; Slim Haddad
Journal:  Health Policy Plan       Date:  2013-12-25       Impact factor: 3.344

9.  Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions.

Authors:  Roger Bate; Richard Tren; Kimberly Hess; Amir Attaran
Journal:  Malar J       Date:  2009-02-25       Impact factor: 2.979

10.  Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.

Authors:  Margaret Kweku; Jayne Webster; Martin Adjuik; Samuel Abudey; Brian Greenwood; Daniel Chandramohan
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.